tbuckley/cabot-search huggingface dataset:
M11 The impact of respiratory speech and language therapy on patients’ cough related symptoms
Authors: J Haines, C Slinger, A Vyas, S Chua, SJ Fowler
Journal: Thorax (2016)

<h3>Introduction</h3> Unexplained chronic cough may persist despite systematic evaluation and medical treatment of relevant comorbidities. Currently there are no effective, acceptable anti-tussive agents for the treatment of such patients and significant physical, social and psychological morbidity is described. The role of non-pharmacological treatment approaches and specifically speech and language therapy have been reported to be effective. In our specialist tertiary airways service, all patients with unexplained chronic cough greater than 8 weeks in duration, remaining unexplained after investigation and supervised therapeutic trials, are referred for respiratory speech and language therapy (rSLT). <h3>Aims</h3> To determine the effect of rSLT on the Leicester Cough Questionnaire (LCQ) and establish specifically whether the impact occurs across each of the described domains: physical, psychological and social. <h3>Methods</h3> We included retrospective data from all patients with unexplained chronic cough who completed rSLT between January and June 2016, and who had LCQ data available before and after treatment. <h3>Results</h3> Sixteeen full data sets [69% female; median (range) age 58 (35–73) years] were available for analysis; rSLT median = 4, (range = 3–6) sessions. There was overall improvement in LCQ from median (range) 13.0 (7.0–18.0) pre to 17.4 (8.0–21.0) post rSLT [minimal important difference (MID) 1.3; Wilcoxon’s signed rank p &lt; 0.001]. Each domain improved post rSLT: physical from 4.7 (3.0–7.0) pre to 6.0 (2.0–7.0) post (MID 0.2; p = 0.004); psychological: from 4.0 (1.0–6.0) to 6.1 (3.0–7.0) (MID 0.8; p = 0.001); and social from 4.0 (2.0–7.0) to 5.7 (3.0–7.0) post (MID 0.2, p = 0.001). Individual answers to 10 of the 19 LCQ questions showed statistically significant improvements. <h3>Conclusion</h3> These preliminary data indicate that rSLT improves cough related symptoms similarly cross all domains. Further investigation is needed to inform which aspects of patients’ cough-related symptoms do/do not improve with therapy to guide treatment refinement. Specifically, closer investigation of response to individual LCQ questions may lead to improvements in therapeutic strategies.
Platelet Mechanosensing: Adhesion and Spreading On Immobilized Fibrinogen Depends On Substrate Stiffness
Authors: Yongzhi Qiu, Ashley C Brown, Woo Jin Jung, Yumiko Sakurai, Robert Mannino, David R Myers, Reginald Tran, Gang Bao, Thomas H Barker, Wilbur Lam
Journal: Blood (2012)
P173 Reduction in non-elective respiratory-related hospitalizations in patients treated with pirfenidone: pooled analyses from three phase 3 trials of pirfenidone in idiopathic pulmonary fibrosis
Authors: B Ley, JJ Swigris, B Day, J Stauffer, W Chou, K Raimundo, H Collard
Journal: Thorax (2016)

<h3>Rationale</h3> Patients with idiopathic pulmonary fibrosis (IPF) are frequently hospitalised for a variety of reasons. Respiratory-related hospitalizations may occur because of acute exacerbations of IPF, respiratory tract infections, respiratory failure and other causes. Regardless of cause, respiratory-related hospitalizations have been linked to poor outcomes in patients with IPF. We describe the proportion of patients from the three Phase 3 pirfenidone IPF trials with at least one non-elective hospitalisation (all-cause, respiratory-related and non-respiratory-related) over 12 months. <h3>Methods</h3> In three Phase 3 randomised, placebo-controlled studies of pirfenidone for IPF (CAPACITY I/II and ASCEND), patients were randomised to pirfenidone (2403 mg/day) or placebo. In the two CAPACITY studies, respiratory-related hospitalizations were a pre-specified endpoint. In ASCEND, hospitalizations were reported as adverse events (AEs), and retrospectively categorised as respiratory-related or non-respiratory by case review. The pooled rates of patients experiencing ≥1 non-elective hospitalizations (all-cause, respiratory-related and non-respiratory-related) for pirfenidone and placebo patients over 12 months are summarised. Rate of death post-hospitalisation was also reported. <h3>Results</h3> A total of 1,247 patients (692 CAPACITY and 555 ASCEND) were included (Table). In pooled analyses, the proportion of patients experiencing ≥1 all-cause hospitalizations over 12 months was no different between pirfenidone and placebo-treated patients. The proportion of patients experiencing ≥1 respiratory-related hospitalizations was 12% in the placebo group vs 7% in the pirfenidone group (odds ratio 0.56; <i>P</i> = 0.004). Deaths after hospitalisation were numerically reduced in the pirfenidone group, most substantially for respiratory-related hospitalizations. <h3>Conclusion</h3> Patients with IPF frequently require hospitalisation for a variety of reasons. Pirfenidone may reduce the risk of non-elective respiratory-related hospitalizations over 12 months.
Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,
Authors: Andrew J. Yee, Anuj K. Mahindra, Paul G. Richardson, Diana D. Cirstea, Tyler A. Scullen, Scott J. Rodig, Teru Hideshima, Parameswaran Hari, Jacob P. Laubach, Irene M. Ghobrial, Robert Schlossman, Nikhil C. Munshi, Edie A. Weller, Kenneth C. Anderson, Noopur S. Raje
Journal: Blood (2011)
Chronic Myeloid Leukemia and BCR/ABL Signal Pathway Are Not Associated with AKT1 Pleckstrin Homology Domain(E17K) Mutations.
Authors: Yanli He, Jine Zheng, Yanjie Hu, Hong Xiao, Huiyu Li, Jun Liu, Xiaoqing Li, Wen Du, Xiangjun Chen, Yu Hu, Shiang Huang
Journal: Blood (2009)
Perioperative Management of Hemostasis with Recombinant FIX Fc Fusion Protein in Subjects Undergoing Surgery in the B-YOND Study
Authors: Margareth Castro Ozelo, Johnny Mahlangu, Godfrey Chan, Margareta Holmstrom, Nicolas Novitzky, David J Perry, Huixing Yuan, Lynda M Cristiano, Baisong Mei
Journal: Blood (2015)
P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)
Authors: Sanjay Popat, Laura Hughes, Mary O'Brien, Tanya Ahmad, Conrad Lewanski, Ulrike Dernedde, Petra Jankowska, Clive Mulatero, Riyaz Shah, Jonathan Hicks, Tom Geldart, Mathilda Cominos, Gill Gray, James Spicer, Karen Bell, Yenting Ngai, Allan Hackshaw
Journal: Journal of Thoracic Oncology (2017)
Lung Gene Expression Analysis (LGEA): an integrative web portal for comprehensive gene expression data analysis in lung development
Authors: Yina Du, Joseph A Kitzmiller, Anusha Sridharan, Anne K Perl, James P Bridges, Ravi S Misra, Gloria S Pryhuber, Thomas J Mariani, Soumyaroop Bhattacharya, Minzhe Guo, S Steven Potter, Phillip Dexheimer, Bruce Aronow, Alan H Jobe, Jeffrey A Whitsett, Yan Xu
Journal: Thorax (2017)

‘LungGENS’, our previously developed web tool for mapping single-cell gene expression in the developing lung, has been well received by the pulmonary research community. With continued support from the ‘LungMAP’ consortium, we extended the scope of the LungGENS database to accommodate transcriptomics data from pulmonary tissues and cells from human and mouse at different stages of lung development. Lung Gene Expression Analysis (LGEA) web portal is an extended version of LungGENS useful for the analysis, display and interpretation of gene expression patterns obtained from single cells, sorted cell populations and whole lung tissues. The LGEA web portal is freely available at http://research.cchmc.org/pbge/lunggens/mainportal.html.
Hepatitis C “true” late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy
Authors: Thomas Klag, Julia Dietz, Christoph R. Werner, Julia M. Schwarz, Ulrich M. Lauer, Robert Beck, Nisar P. Malek, Christoph Sarrazin, Christoph P. Berg
Journal: Journal of Hepatology (2017)
Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response
Authors: Birgit Lehmann, Markus Biburger, Christin Brückner, Andrea Ipsen-Escobedo, Sina Gordan, Christian Lehmann, David Voehringer, Thomas Winkler, Niels Schaft, Diana Dudziak, Horia Sirbu, Georg F. Weber, Falk Nimmerjahn
Journal: Science Immunology (2017)

Despite recent advances in activating immune cells to target tumors, the presence of some immune cells, such as tumor-associated macrophages (TAMs) or tumor-associated neutrophils (TANs), may promote rather than inhibit tumor growth. However, it remains unclear how antibody-dependent tumor immunotherapies, such as cytotoxic or checkpoint control antibodies, affect different TAM or TAN populations, which abundantly express activating Fcγ receptors. In this study, we show that the tissue environment determines which cellular effector pathways are responsible for antibody-dependent tumor immunotherapy. Although TAMs derived from Ly6Chigh monocytes recruited by the CCL2-CCR2 axis were critical for tumor immunotherapy of skin tumors, the destruction of lung tumors was CCL2-independent and required the presence of colony-stimulating factor 2-dependent tissue-resident macrophages. Our findings suggest that TAMs may have a dual role not only in promoting tumor growth in certain tissue environments on the one hand but also in contributing to tumor cell destruction during antibody-mediated immunotherapy on the other hand.
P1.05-040 Prognostic Factor of Node Involvement Pattern in Completely Resected pN1 Squamous Cell Carcinoma Patients
Authors: Kenta Tane, Kenji Miura, Hiromichi Okuma, Yoshitaka Kitamura, Wataru Nishio, Masahiro Yoshimura
Journal: Journal of Thoracic Oncology (2017)
PUB113 Organs at Risk Contouring in Lung Cancer Radiation Therapy: An Anatomo-Radiological Atlas
Authors: Maria Taraborrelli, Marianna Nuzzo, Annamaria Vinciguerra, Marianna Trignani, Francesca Perrotti, Clelia Di Carlo, Saide Di Biase, Consuelo Rosa, Domenico Genovesi
Journal: Journal of Thoracic Oncology (2017)
Prescribing and guidelines: both must improve to combat antimicrobial resistance
Authors: M. Woodhead
Journal: European Respiratory Journal (2011)

The problem is the development and spread of antimicrobial resistance in common bacterial pathogens. The cause is excessive exposure of these bacteria to antimicrobial agents. The solution is to reduce antimicrobial exposure, the most important element of which is to reduce human use.

Most human exposure occurs through antimicrobial prescription in the community, the most common reason for which is presumed respiratory infection. Human exposure varies widely between European countries, with the same patient being, on average, four times more likely to receive an antibiotic in France compared to the Netherlands [1]; a difference that cannot be explained by the scientific evidence base. Clearly there are respiratory infections where antimicrobial use is an essential part of management, so the name of the game is to promote “prudent” or “appropriate” antimicrobial prescribing. There is no single strategy that will lead to prudent prescribing, as elements such as agreement as to what is or is not prudent, medical education and public education all play a part. One important element is medical education through the use of clinical practice guidelines. The European Council has recommended that member states, as part of control and preventive measures (for antimicrobial resistance), “develop[ing] evidence-based principles and guidelines on good practice for the management of communicable diseases, to maintain the effectiveness of antimicrobial agents” [2]. European Respiratory Journal ( ERJ ) readers will be aware of the guidelines for the management of lower respiratory tract infections developed jointly by the European Respiratory Society (ERS) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), part of which was directed to the promotion of appropriate antimicrobial practice for adult lower respiratory tract infection (LRTI) in the community [3]. The guidelines recommended that antibiotics should be considered in LRTI in the community only in the …
High Incidence of Autoimmune Complications during Combined Fludarabine and Rituximab Therapy in CLL: Rapid Clearance of Rituximab as a Contributing Factor
Authors: Ndegwa Njuguna, Paul V Beum, Berengere Vire, Gerald E Marti, Therese White, Wyndham H. Wilson, Ronald P Taylor, Adrian Wiestner
Journal: Blood (2008)
OA04.02 Smoking Behavior in Patients with Early Stage Non-Small Cell Lung Cancer: A Report from ECOG-ACRIN 1505 Trial
Authors: Suresh Ramalingam, Suzanne Dahlberg, Heather Wakelee, Steven Keller, William Tester, David R. Gandara, Stephen Graziano, Alex Adjei, Charles Butts, Joan Schiller
Journal: Journal of Thoracic Oncology (2017)
P1.08-056 Surgical Results of Thoracoscopic Anatomical Sublobar Resections for Early-Stage Lung Cancer
Authors: Fumiaki Watanabe, Motoshi Takao, Kosuke Hayashi, Isao Yada, Hideto Shimpo, Yuta Suzuki, Haruko Saiki, Tadashi Sakaguchi, Kentaro Ito, Yoichi Nishii, Osamu Hataji
Journal: Journal of Thoracic Oncology (2017)
A smart aminoglycoside hydrogel with tunable gel degradation, on-demand drug release, and high antibacterial activity
Authors: Jingjing Hu, Yanchun Quan, Yuping Lai, Zhao Zheng, Zhiqi Hu, Xinyu Wang, Tianjiao Dai, Qiang Zhang, Yiyun Cheng
Journal: Journal of Controlled Release (2017)
P25 Retrospective analysis of patients presenting with acute pulmonary embolism (pe) as the first manifestation of malignancy
Authors: A Murchison, A Asher, A Van Manen, H Ellis
Journal: Thorax (2016)

<h3>Introduction</h3> A link between development of PE and presence of malignancy has long been established. NICE recommends patients presenting with PE should be offered: history, examination, chest x-ray and urinalysis. Further investigation for cancer with abdomino-pelvic CT (CT A/P) scan in patients over 40 with a first unprovoked PE should be considered.<sup>1</sup> CT screening has not been shown to improve occult cancer diagnosis or mortality from cancer.<sup>2</sup> <h3>Methods</h3> We conducted a retrospective review of patients diagnosed with new PE at Milton Keynes hospital between August 2014 and 2015 to determine the proportion of patients found to have malignancy after CT. Selected patient notes were interrogated for clinical and laboratory findings at the time of diagnosis, and for details of subsequent management. <h3>Results</h3> 177 patients were included in our study. 102 received a CT A/P, 88 of whom did not have an established diagnosis of cancer. Out of the 88, 5 new diagnoses of cancer were made. In 10 cases, CT revealed incidental findings. 8 patients received further imaging, and 2 investigated with invasive procedures. 4 of the 5 new cancer diagnoses had abnormal findings after basic screening. Standardised incidence ratios were calculated to assess the probability of presence of undiagnosed cancer in patients presenting with PE. Our data showed no significant increase in the incidence of cancer in patients presenting with PE compared to national cancer statistics (SIR of 0.75 in males (CI: 0.2–0.64) and 1.0 in females (CI: 0.23–0.56) aged 70–79). <h3>Discussion</h3> Our data suggests that in patients presenting with acute PE, clinical acumen (as outlined by NICE) can be used to identify patients with potential malignancy. Our data would support limiting CT A/P to patients with significant clinical features or deranged tests. <h3>References</h3> National Institute for Health and Clinical Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. CG144. <i>NICE</i>2015. Carrier M, Lazo-Langner A, Shivakumar S, <i>et al</i>. Screening for occult cancer in unprovoked venous thromboembolism. <i>New England Journal of Medicine</i> 2015;<b>373</b>(8):697–704.
Hepatectomy for Early Hepatocellular Carcinoma
Authors: Roberto Hernandez-Alejandro, Mark A. Levstik, David C. Linehan
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
MA05.05 Genomic Profiles of Lung Cancer Associated with Idiopathic Pulmonary Fibrosis
Authors: Ji An Hwang, Deokhoon Kim, Soo Hyun Bae, Sung-Min Chun, Joon Seon Song, Mi Young Kim, Jin Woo Song, Woo Sung Kim, Jae Cheol Lee, Sojung Park, Hyeong Ryul Kim, Chang-Min Choi, Se Jin Jang
Journal: Journal of Thoracic Oncology (2017)
P3.02b-053 A Randomized, Open Label, Phase II Study Comparing Pemetrexed plus Cisplatin versus Pemetrexed Alone in EGFR Mutant NSCLC after EGFR-TKI: QOL Data
Authors: Kwai Han Yoo, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Kyung A. Kwon, Heuijune Ahn, Hye Ryun Kim, Hoon-Gu Kim, Ha Yeon Lee, Hwan Jung Yun, Jin Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Journal: Journal of Thoracic Oncology (2017)
The Novel Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Engraftment in Irradiated NOD/SCID Mice: What Did We Learn?
Authors: Omar S. Aljitawi, Jeff Radel, Bruce Kimler, Jeff Eskew, Nikhil Parelkar, Megan Swink, Rama Garimella, Lei (Isaac) Dong, Joseph McGuirk, George Vielhauer
Journal: Blood (2011)
A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent Mechanism
Authors: Dharminder Chauhan, Madhavi Bandi, Ajita V Singh, Teru Hideshima, Nikhil C. Munshi, Paul G Richardson, Kenneth C. Anderson
Journal: Blood (2010)
P3.02a-022 Experiences of Patients Receiving Treatment with Ceritinib to Treat ALK+ Non-Small Cell Lung Cancer: A Qualitative Study
Authors: Jennifer Devlen, France Ginchereau Sowell, Gabrielle Quiggle, Emuella Flood, Kenneth Culver, Anand Dalal
Journal: Journal of Thoracic Oncology (2017)
P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold B
Authors: R Buhl, L McGarvey, S Korn, GT Ferguson, L Grönke, C Hallmann, F Voß, KF Rabe, F Maltais
Journal: Thorax (2016)

<h3>Rationale</h3> The once-daily combination of tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β<sub>2</sub>-agonist, has demonstrated efficacy and safety in COPD. Two large clinical studies (TONADO<sup>®</sup>1 + 2) have also demonstrated the benefits of T/O compared to the monocomponents in patients with moderate to very severe COPD. This <i>post hoc</i> analysis investigated whether T/O is more effective than T at delaying clinically significant events in patients with GOLD stage B COPD. <h3>Methods</h3> A total of 5162 patients were randomised to O 5 µg, T 2.5 µg, T 5 µg, T/O 2.5/5 µg or T/O 5/5 µg (delivered via Respimat<sup>®</sup> inhaler) in two 52-week, parallel-group, double-blind studies (NCT01431274; NCT01431287). In this <i>post hoc</i> analysis of the combined TONADO<sup>®</sup> data, clinical deterioration was defined according to a composite end point: time to first decrease in trough forced expiratory volume in 1 second (FEV<sub>1</sub>) from baseline of ≥100 mL; increase in St George’s Respiratory Questionnaire (SGRQ) total score from baseline of ≥4 units; severe (hospitalised) exacerbation; or death. Only patients classified as GOLD stage B were included. Data are presented for comparisons of the licensed doses of T 5 µg and T/O 5/5 µg. <h3>Results</h3> 306 and 310 patients were included in this analysis in the T 5 µg and T/O 5/5 µg treatment groups, respectively. Time to clinical deterioration was significantly longer with T/O 5/5 µg than T 5 µg (25th percentile 128 versus 85 days; HR 0.650; 95% CI: 0.524, 0.805; p &lt; 0.0001) (Figure). Times to trough FEV<sub>1</sub> decline and SGRQ increase were significantly longer with T/O 5/5 µg than T 5 µg (226 versus 91 days and 369 versus 175 days, respectively). 25<sup>th</sup> percentiles for time to severe exacerbation and time to death were not estimable due to low event rates. <h3>Conclusions</h3> In the TONADO<sup>®</sup> studies, T/O increased time to clinical deterioration compared to T alone in patients with GOLD stage B disease. This suggests that, in this patient population, T/O is more effective than T in preventing these significant events. Further studies are warranted to prospectively study this effect. <h3>Funding</h3> Boehringer Ingelheim. Please refer to page A272 for declarations of interest in relation to abstract P294.
Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I
Authors: Marielle Brockhoff, Nathalie Rion, Kathrin Chojnowska, Tatiana Wiktorowicz, Christopher Eickhorst, Beat Erne, Stephan Frank, Corrado Angelini, Denis Furling, Markus A. Rüegg, Michael Sinnreich, Perrine Castets
Journal: Journal of Clinical Investigation (2017)

Myotonic dystrophy type I (DM1) is a disabling multisystemic disease that predominantly affects skeletal muscle. It is caused by expanded CTG repeats in the 3'-UTR of the dystrophia myotonica protein kinase (DMPK) gene. RNA hairpins formed by elongated DMPK transcripts sequester RNA-binding proteins, leading to mis-splicing of numerous pre-mRNAs. Here, we have investigated whether DM1-associated muscle pathology is related to deregulation of central metabolic pathways, which may identify potential therapeutic targets for the disease. In a well-characterized mouse model for DM1 (HSALR mice), activation of AMPK signaling in muscle was impaired under starved conditions, while mTORC1 signaling remained active. In parallel, autophagic flux was perturbed in HSALR muscle and in cultured human DM1 myotubes. Pharmacological approaches targeting AMPK/mTORC1 signaling greatly ameliorated muscle function in HSALR mice. AICAR, an AMPK activator, led to a strong reduction of myotonia, which was accompanied by partial correction of misregulated alternative splicing. Rapamycin, an mTORC1 inhibitor, improved muscle relaxation and increased muscle force in HSALR mice without affecting splicing. These findings highlight the involvement of AMPK/mTORC1 deregulation in DM1 muscle pathophysiology and may open potential avenues for the treatment of this disease.
P2.04-020 Expression Patterns and Prognostic Value of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma
Authors: Dwight Owen, Benjamin Chu, Amy Lehman, Lakshmanan Annamalai, Jennifer Yearley, Konstantin Shilo, Gregory Otterson
Journal: Journal of Thoracic Oncology (2017)
P2.05-015 Long-Term Outcomes of Prospective Phase П Clinical Trial for Stereotactic Ablation Radiotherapy in Recurrent NSCLC
Authors: Joe Chang, Bing Sun, Zhongxing Liao, Melenda Jeter, James Welsh, Peter Balter, Reza Mehran, John Heymach, Ritsuko Komaki, Jack Roth
Journal: Journal of Thoracic Oncology (2017)
P1.05-028 Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC)
Authors: Lorenzo Federico, Cara Haymaker, Marie-Andrée Forget, Luis Vence, Icon Team, Padmanee Sharma, James Allison, Bingliang Fang, Jianjun Zhang, Heidi Wagner, Elena Bogatenkova, Ignacio Wistuba, Boris Sepesi, John Heymach, Don Lynn Gibbons, Chantale Bernatchez
Journal: Journal of Thoracic Oncology (2017)